CEL-SCI Corporation (CVM) investor relations documents from the company's IR site: 3 presentations, 1 press release; latest deck 2026-05-17. Read in-app with summaries. First-party data.
General Presentation: CEL-SCI is developing Multikine, a non-toxic immunotherapy for head and neck cancer, targeting a 2028 FDA approval following a 212-patient confirmatory Phase 3 study.
| Published | Type | Document |
|---|---|---|
| 2026-05-17 | Presentation | General Presentation |
| 2024-06-14 | Presentation | June 18, 2024 - Scientific Presentation by CEL-SCI Chief Scientific Officer, Eyal Talor, Ph.D. |
| 2024-05-08 | Press release | May 8, 2024 |
| 2023-03-20 | Presentation | CEL-SCI Research Report by Crystal Research Associates |
CVM overview · CVM earnings · CVM financials · CVM KPIs · CVM ownership · CVM peers · CVM filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.